Yesterday, a US District Court judge issued a ruling which invalidated the patents on the BRCA1 and BRCA2 genes. The patent-holder, Myriad Genetics, sells genetic testing services that predict likelihoods of getting breast cancer: women with certain mutations in these genes have an 85% lifetime chance of getting breast cancer, unless they get
(
Read more... )
Comments 2
Reply
Reply
Leave a comment